Literature DB >> 6257204

Genesis of 1,2-dimethylhydrazine-induced colon cancer. A light and electron microscopic study.

E R Fisher, J D Paulson, M M McCoy.   

Abstract

Rats treated with 1,2-dimethylhydrazine (DMH) exhibited colonic mucosal dysplastic foci prior to the development of tumors. Ultrastructurally, these, as well as the cancers that subsequently developed, were characterized by alterations in plasma membranes and an increase in cytoplasmic ribosomal particles, principally in stem cells and their absorptive derivatives. Rare Kulchitsky cells appeared preserved, but the mucin-producing or goblet-cell elements were compressed and atrophic. In addition, nuclear aberrations were more pronounced in the cancer than in the dysplastic foci. The principal ultrastructural difference between the so-called well-differentiated and mucinous forms of DMH-induced cancers was the presence of frequent intracytoplasmic lumens in the mucinous form. Such structures represented the analogues of signet ring cells observed by light microscopy. This experimental model of human colonic cancer shows that the mucosal stem-cell and dysplastic lesions represent their cytogenetic and histogenetic progenitors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6257204

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Rodent models for carcinoma of the colon.

Authors:  A E Rogers; K M Nauss
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

2.  The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.

Authors:  A E Davis; F Patterson; R Crouch
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

3.  A new rat colon cancer cell line metastasizes spontaneously: biologic characteristics and chemotherapeutic response.

Authors:  Y Inoue; Y Kashima; K Aizawa; K Hatakeyama
Journal:  Jpn J Cancer Res       Date:  1991-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.